26 completed, 2 active not recruiting, 2 not yet recruiting, 1 recruiting. 17 Phase 2, 8 Phase 1, 2 Not applicable, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 17 | Completed 12, Active not recruiting 2, Not yet recruiting 2, Withdrawn 1 |
| Phase 1 | 8 | Completed 5, Not yet recruiting 2, Recruiting 1 |
| Not applicable | 2 | Completed 2 |
| Phase 3 | 1 | Completed 1 |
Follow Recurrent Childhood Rhabdomyosarcoma: new trials by email Literature Review of Recurrent Childhood Rhabdomyosarcoma trials Research Report on Recurrent Childhood Rhabdomyosarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1/2 Study of CBX-12 in Children, Adolescents, or Young Adults With Solid Tumors That Have Come Back After Treatment or Are Difficult to Treat Archive Sample Retrieval, Biospecimen Collection, pH Low Insertion Peptide-exatecan Conjugate CBX-12 - Recurrent Childhood Ewing Sarcoma, Recurrent Childhood Malignant Solid Neoplasm | Phase 1 / Phase 2 | Not yet recruiting | Children's Oncology Group | 79 | 2027-05-07 | 2026-09-22 |
| Testing the Addition of an Anti-Cancer Drug, Daraxonrasib, for Relapsed or Refractory Solid Tumors With RAS Mutations Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Childhood Malignant Solid Neoplasm, Recurrent Childhood Neuroblastoma | Phase 1 / Phase 2 | Not yet recruiting | Children's Oncology Group | 77 | 2027-04-09 | 2026-09-15 |
| Retrospective Study in FFPE Samples From Younger Patients With Rhabdomyosarcoma Alveolar Childhood Rhabdomyosarcoma, Embryonal Childhood Rhabdomyosarcoma | Completed | Shandong First Medical University | 6 | 2023-04-01 | 2023-09-15 | |
| Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling Functional Precision Medicine - Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia | Phase 1 | Recruiting | Florida International University | 65 | 2023-02-22 | 2026-08-26 |
| Ex Vivo Drug Sensitivity Testing and Mutation Profiling Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia | Completed | Florida International University | 25 | 2019-02-21 | 2023-05-10 | |
| Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan - Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 20 | 2018-06-05 | 2026-10-16 |
| Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) Olaparib - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 6 | 2017-09-14 | 2024-12-11 |
| Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration and Biopsy - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 1377 | 2017-07-31 | 2026-07-24 |
| Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors Imetelstat Sodium, Laboratory Biomarker Analysis - Hepatoblastoma, Previously Treated Childhood Rhabdomyosarcoma | Phase 2 | Withdrawn | Children's Oncology Group | 2014-06-30 | 2018-08-07 | |
| Biomarkers in Patients With Advanced Rhabdomyosarcoma Laboratory Biomarker Analysis - Adult Rhabdomyosarcoma, Childhood Alveolar Rhabdomyosarcoma | Completed | Children's Oncology Group | 10 | 2012-08-01 | 2016-05-18 | |
| Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma Cixutumumab, Laboratory Biomarker Analysis, Temsirolimus - Childhood Alveolar Soft Part Sarcoma, Childhood Angiosarcoma | Phase 2 | Completed | National Cancer Institute (NCI) | 46 | 2012-06-18 | 2018-12-11 |
| Studying Mechanisms of Radiation Therapy Resistance in Samples From Younger Patients With Rhabdomyosarcoma laboratory biomarker analysis - Alveolar Childhood Rhabdomyosarcoma, Embryonal Childhood Rhabdomyosarcoma | Completed | Children's Oncology Group | 20 | 2012-06-01 | 2016-07-14 | |
| Studying Protein Expression in Tissue Samples From Younger Patients With Rhabdomyosarcoma laboratory biomarker analysis - Alveolar Childhood Rhabdomyosarcoma, Embryonal Childhood Rhabdomyosarcoma | Completed | Children's Oncology Group | 99 | 2012-06-01 | 2016-05-18 | |
| Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer sorafenib tosylate, pharmacological study, laboratory biomarker analysis - Childhood Hepatocellular Carcinoma, Papillary Thyroid Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 20 | 2012-01-01 | 2018-06-26 |
| Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant supersaturated calcium phosphate rinse, placebo, questionnaire administration - Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission | Phase 3 | Completed | Children's Oncology Group | 226 | 2011-03-01 | 2019-09-17 |
| Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia Alisertib, Laboratory Biomarker Analysis, Pharmacological Study - Hepatoblastoma, Previously Treated Childhood Rhabdomyosarcoma | Phase 2 | Completed | Children's Oncology Group | 118 | 2011-02-01 | 2020-05-13 |
| Intensity-Modulated Radiation Therapy in Treating Younger Patients With Lung Metastases intensity-modulated radiation therapy - Adult Rhabdomyosarcoma, Lung Metastases | Not applicable | Completed | Ann & Robert H Lurie Children's Hospital of Chicago | 20 | 2011-02-01 | 2025-02-10 |
| Vinorelbine Tartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma Bevacizumab, Cyclophosphamide, Laboratory Biomarker Analysis - Adult Rhabdomyosarcoma, Childhood Alveolar Rhabdomyosarcoma | Phase 2 | Completed | National Cancer Institute (NCI) | 87 | 2010-10-01 | 2017-05-05 |
| Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors cixutumumab, laboratory biomarker analysis - Adult Rhabdomyosarcoma, Adult Synovial Sarcoma | Phase 2 | Completed | National Cancer Institute (NCI) | 116 | 2009-01-01 | 2015-03-30 |
| Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma Cixutumumab, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis - Adult Angiosarcoma, Adult Desmoplastic Small Round Cell Tumor | Phase 1 | Completed | National Cancer Institute (NCI) | 30 | 2008-06-01 | 2016-05-17 |
Showing 20 of 32. Sign in to see all of them.
Neuroblastoma (15) · Neuroectodermal Tumors, Primitive, Peripheral (13) · Osteosarcoma (13) · Rhabdomyosarcoma (12) · Wilms Tumor (12) · Sarcoma (10) · Familial ependymoma (9) · Dendritic Cell Sarcoma, Interdigitating (7) · Hepatoblastoma (7) · Medulloblastoma (7) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (7) · Astrocytoma (5) · Burkitt Lymphoma (5) · Recurrence (5) · Sarcoma, Ewing (5)
Neoplasms by Histologic Type (27) · Neoplasms (26) · Neoplasms, Connective and Soft Tissue (20) · Neoplasms, Connective Tissue (18) · Neoplasms, Germ Cell and Embryonal (18) · Neoplasms, Glandular and Epithelial (18) · Neoplasms, Nerve Tissue (18) · Neoplasms, Neuroepithelial (17) · Neuroectodermal Tumors, Primitive (17) · Neoplasms, Bone Tissue (16) · Neuroectodermal Tumors (16) · Neoplasms, Complex and Mixed (15) · Neoplasms by Site (14) · Female Urogenital Diseases (13) · Female Urogenital Diseases and Pregnancy Complications (13)
Specimen Handling (4) · Biopsy (3) · Irinotecan (3) · Phantoms, Imaging (3) · X-Rays (3) · cixutumumab (3) · Cyclophosphamide (2) · Doxorubicin (2) · Magnetic Resonance Spectroscopy (2) · Nuclear Medicine Department, Hospital (2) · Oxaliplatin (2) · Sirolimus (2) · erdafitinib (2) · olaparib (2) · temsirolimus (2)
National Cancer Institute (NCI) (15) · Children's Oncology Group (12) · Florida International University (2) · Ann & Robert H Lurie Children's Hospital of Chicago (1) · Fred Hutchinson Cancer Center (1) · Shandong First Medical University (1)
United States (28) · Canada (9) · Australia (6) · Puerto Rico (4) · New Zealand (2) · China (1) · Netherlands (1) · Switzerland (1)
AeRang Kim, MD (1) · Alice Lee (1) · Amit J Sabnis (1) · Brenda Weigel, MD (1) · Brigitte Widemann (1) · Charles Keller, MD (1) · Christopher Pelloski, MD (1) · Daria Salyakina, PhD (1) · David Walterhouse (1) · Diana Azzam (1) · Diana Azzam, PhD (1) · Donald W Parsons (1) · Frederick Barr, MD (1) · Gregory Yanik, MD (1) · James Whitlock (1)
PMID 31401903, PMID 22088484, PMID 25858498, PMID 28817727, PMID 30777875, PMID 31513481, PMID 33591402, PMID 34435684, PMID 34738048, PMID 35353553, PMID 38605166, PMID 38815151, PMID 41166674, PMID 42686334
U10CA098543 (12), U01CA097452 (3), U10CA180886 (3), UM1CA228823 (2), N01CM00071 (1), P30CA014599 (1), R21CA159547 (1), U01CA069856 (1), U10CA024507 (1), U10CA095861 (1), U54MD012393 (1), UG1CA189958 (1), UM1CA081457 (1)